Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US ...Middle East

PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb)...

Hence then, the article about fosun pharma and henlius entered into an exclusive license agreement for serplulimab in the us was published today ( Saturday 07/01/2023 - 01:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US )

Also on site :

• Philippines volcano erupts, blanketing ash across the sky
• 1970 Soft Rock Classic, That Became a Career-Defining Song for ’70s Legend, Ranked Among ‘Greatest Songs of All Time’
• Khartoum drone strike kills five Sudan NGO reports